Mar 12, 2019 / 12:00PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD and Senior Research Analyst
Well, good morning, and welcome to the AbbVie session at the Cowen conference. We're very pleased to have the company back, again, with us this year. Representing the company, Mike Severino, who is Vice Chairman and President; and Rob Michael, who is Senior Vice President and CFO.
As many of you may know, we believe at Cowen that this stock represents a very compelling idea right now. And what are the reasons for that? Well, how many pharma stocks do you know that have 4 products in development, and maybe 5, that have multibillion-dollar potential? Second, yes, HUMIRA represents a significant hurdle, but we believe the company has done as good a job as they possibly could have to protect themselves in the U.S. and to blunt the erosion in Europe. Thirdly, of course, the stock is very attractively valued. And you put it all together, and we think that this represents a very good time to be kicking the tires on AbbVie. And this is a great opportunity with 2 members of senior management with us today. So
AbbVie Inc at Cowen and Company Health Care Conference Transcript
Mar 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers